Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CannaRiver CBD Calm in Adults With Generalized Anxiety Disorder
NCT07821840Not yet recruiting
- Sponsor
- APAME
- Start
- Nov 2026
- Primary completion
- Mar 2027
01
Overview
Open-label, single-arm trial of CannaRiver CBD Calm in generalized anxiety disorder (GAD), sponsored by APAME. Primary endpoint: Generalized Anxiety Disorder 7-Item Scale at 8 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
CannaRiver CBD Calm
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT07821840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07821840.